×
About 2,055 results

ALLMedicine™ Gallbladder Cancer Center

Research & Reviews  764 results

Trend analysis and risk of gallbladder cancer mortality in China, 2013-2019.
https://doi.org/10.1016/j.puhe.2021.12.002
Public Health; Nie C, Yang T et. al.

Jan 14th, 2022 - There is a lack of comprehensive analysis of recent gallbladder cancer (GBC) mortality trends in China. This study aims to analyse trends in GBC mortality in China, with a specific focus on urban and rural area differences, and to determine possib...

Surgical practice patterns and outcomes in T2 and T3 gallbladder cancer: a population-b...
https://doi.org/10.1503/cjs.019719
Canadian Journal of Surgery. Journal Canadien De Chirurgie; Tharmalingam S, Flemming J et. al.

Jan 13th, 2022 - The extent of resection required in advanced gallbladder cancer is controversial. We aimed to describe the management and outcomes in patients with resected stage T2 and T3 gallbladder cancer. In this population-based study, all T2 and T3 gallblad...

Transcriptional repression and apoptosis influence the effect of APOBEC3A/3B functional...
https://doi.org/10.1002/ijc.33930
International Journal of Cancer; Liu W, Ji H et. al.

Jan 13th, 2022 - APOBEC3-related somatic mutations are predominant in biliary tract cancers (BTCs). We aimed to elucidate the roles of APOBEC3A/3B functional polymorphisms and their influencing factors on the development of cholangiocarcinoma and gallbladder cance...

Meta-analysis of the diagnostic performance of serum carbohydrate antigen 19-9 for the ...
https://doi.org/10.1177/17246008211068866
The International Journal of Biological Markers; Zhou X

Jan 5th, 2022 - Carbohydrate antigen 19-9 (CA19-9) is a well-studied tumor marker, yet its diagnostic value for gallbladder cancer remains unclear. The present meta-analysis was conducted to validate the role of serum CA19-9 for the detection of gallbladder cance...

see more →

Guidelines  5 results

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2021.0022
Journal of the National Comprehensive Cancer Network : JN... Benson AB, D'Angelica MI et. al.

May 25th, 2021 - The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcino...

Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd ...
https://doi.org/10.1002/jhbp.870
Journal of Hepato-biliary-pancreatic Sciences; Nagino M, Hirano S et. al.

Dec 2nd, 2020 - The Japanese Society of Hepato-Biliary-Pancreatic Surgery launched the clinical practice guidelines for the management of biliary tract cancers (cholangiocarcinoma, gallbladder cancer, and ampullary cancer) in 2007, then published the 2nd version ...

AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With...
https://doi.org/10.1016/j.cgh.2019.07.011
Clinical Gastroenterology and Hepatology : the Official C... Bowlus CL, Lim JK et. al.

Jul 16th, 2019 - The purpose of this clinical practice update is to define key principles in the surveillance of hepatobiliary cancers including cholangiocarcinoma, gallbladder adenocarcinoma, and hepatocellular carcinoma in patients with primary sclerosing cholan...

Gallbladder cancer: expert consensus statement.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527853
HPB : the Official Journal of the International Hepato Pa... Aloia TA, Járufe N et. al.

Jul 15th, 2015 - An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus meeting of expert panellists was convened on 15 January 2014 to review current evidence on the management of gallbladder carcinoma in order to establish practice guidelin...

Modification and implementation of NCCN guidelines on hepatobiliary cancers in the Midd...
https://doi.org/10.6004/jnccn.2010.0123
Journal of the National Comprehensive Cancer Network : JN... Yusuf MA, Kapoor VK et. al.

May 11th, 2011 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Hepatobiliary Cancers address hepatocellular cancer, cancer of the gallbladder, extrahepatic cholangiocarcinoma, and intrahepatic cholangiocarcinoma. Hepatocellular cancer inci...

see more →

Clinicaltrials.gov  15 results

A Study of ABL001 in Combination With Irinotecan or Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04492033

Aug 12th, 2021 - Phase 1b Study: Indication of phase 1b study is the advanced or metastatic solid tumors (including, but not limited to, colorectal cancer, gastric cancer, and ovarian cancer). Phase 2 Study: Indication of phase 2 study is unresectable advanced, me...

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
https://clinicaltrials.gov/ct2/show/NCT03201458

Jul 13th, 2021 - PRIMARY OBJECTIVE: I. To assess the progression free survival (PFS) of patients receiving atezolizumab monotherapy and cobimetinib in combination with atezolizumab for unresectable cholangiocarcinoma. SECONDARY OBJECTIVES: I. To assess the overall...

Adjuvant Chemotherapy vs no Chemotherapy for Patients With GallBllader Carcinoma
https://clinicaltrials.gov/ct2/show/NCT02778308

Apr 6th, 2021 - Carcinoma of the gallbladder is the commonest malignancy of the biliary tract. United states has an incidence of 1/100000.Higher incidence has been noted in Chile, Mexico and Southwest American Indians. It is the third most common malignancy in In...

Feasibility of EUS-guided Biliary Drainage With LAMS for the Treatmentof Patients With Distal Malignant Biliary Obstruction
https://clinicaltrials.gov/ct2/show/NCT04723199

Jan 26th, 2021 - Distal malignant biliary obstruction results from different types of tumors including pancreatic cancer, biliary tract cancer (BTC), gallbladder cancer, and metastasis, which can lead to obstructive jaundice. Endoscopic retrograde cholangiopancrea...

Survival and Description of Care for Patients With Degenerate Vaterian Ampulloma
https://clinicaltrials.gov/ct2/show/NCT03800212

Nov 6th, 2020 - A Vater's ampulloma is a rare digestive tumour which accounts for under 1% of all digestive tumours. In terms of incidence, it is the 3rd most common biliary tract tumour after gallbladder cancer and common bile duct cancer. The incidence of ampul...

see more →

News  33 results

Fast Five Quiz: Gallbladder Disease
https://reference.medscape.com/viewarticle/964010

Dec 8th, 2021 - Gallbladder disease is a broad term that can refer to infection, inflammation, or biliary blockage due to gallstones. From cholecystitis to gallbladder cancer, these conditions are both common and costly. Can you recognize common gallbladder disea...

Hair Products and Breast Cancer; CRS After COVID Vax; Good Bacteria and Chemo
https://www.medpagetoday.com/hematologyoncology/othercancers/92817

May 27th, 2021 - Researchers found that moderate use of hair relaxers -- products commonly used by Black women and that can contain estrogens or estrogen-disrupting compounds -- did not increase the overall risk of breast cancer. (Boston University School of Medic...

Advanced Glycation Endproducts and Liver Cancer: Findings Unexpected, Show Inverse Relationship
https://www.medscape.com/viewarticle/951914

May 26th, 2021 - Contrary to expectations, high dietary intake of advanced glycation endproducts (AGEs), including those from foods that are deep fried, grilled, or broiled, was associated with a lower risk of hepatocellular carcinoma (HCC) in a large, multination...

Second Resections in Gallbladder Cancer Tied to Better OS, but Barely Used
https://www.medpagetoday.com/hematologyoncology/othercancers/92769

May 24th, 2021 - Second definitive surgery in gallbladder cancer was associated with improved overall survival (OS), a retrospective study found, but the practice goes largely underutilized. In a study of 6,175 patients, those who underwent re-resection -- defined...

Mutual Exclusivity in CCA
https://www.onclive.com/view/mutual-exclusivity-in-cca

Apr 2nd, 2021 - Transcript: Ghassan Abou-Alfa, MD, MBA: I’ll go back to Andrew. We briefly carried out some of that discussion, but we’ll go into more details. Tell us a little bit more about this mutual exclusivity in cholangiocarcinoma of different mutations...

see more →

Patient Education  5 results see all →